Cas:1016636-76-2 6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one manufacturer & supplier

Chemical Name:6-broMo-2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one

CAS.NO:1016636-76-2

Synonyms:6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one;QC-4423;Pyrido[2,3-d]pyrimidin-7(8H)-one,6-bromo-2-chloro-8-cyclopentyl-5-methyl;Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-bromo-2-chloro-8-cyclopentyl-5-methyl-

Molecular Formula:C₁₃H₁₃BrClN₃O

Molecular Weight:342.619

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:468.4±45.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.655

PSA:47.78000

Exact Mass:340.993042

LogP:2.13

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-Bromo-2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-bromo-2-chloro-8-cyclopentyl-5-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyrido[2,3-d]pyrimidin-7(8H)-one,6-bromo-2-chloro-8-cyclopentyl-5-methyl Use and application,QC-4423 technical grade,usp/ep/jp grade.

Related News: For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. Physician-led and privately owned, ChenMed is a provider of choice for some 20 Medicare Advantage health insurance plans. 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(1,3-thiazol-4-ylmethyl)-1,8-naphthyridin-2(1H)-one sodium salt manufacturers The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. 3-Ethylsulfanyl-5-methyl-cyclohex-4-ene-1,1,2,2-tetracarbonitrile suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 1,4-bis-(2-benzhydryloxy-ethyl)-piperazine vendor & factory.